NASDAQ:GLMD Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free GLMD Stock Alerts $0.33 -0.03 (-8.27%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.33▼$0.3850-Day Range$0.34▼$0.4252-Week Range$0.26▼$5.47Volume106,941 shsAverage Volume53,423 shsMarket Capitalization$1.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Galmed Pharmaceuticals alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Read More GLMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLMD Stock News HeadlinesJune 11, 2024 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.comApril 13, 2024 | fool.comGalmed Pharmaceuticals (NASDAQ: GLMD)April 10, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 4, 2024 | prnewswire.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023March 15, 2024 | markets.businessinsider.comGalmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver FibrosisMarch 15, 2024 | prnewswire.comGalmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisFebruary 13, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd (GPH.BE)January 3, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd. (GPH.F)November 20, 2023 | finance.yahoo.comGalmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNovember 4, 2023 | morningstar.comGalmed Pharmaceuticals Ltd GLMDSeptember 26, 2023 | finance.yahoo.comGalmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisAugust 3, 2023 | nasdaq.comGalmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08July 14, 2023 | marketwatch.comGalmed Pharma Shares Drop 30% After Public Offering PricesJuly 14, 2023 | seekingalpha.comGalmed shares slump on pricing discounted stock and warrants offeringJuly 14, 2023 | finance.yahoo.comGalmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingJuly 13, 2023 | investorplace.comWhy Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?July 10, 2023 | finance.yahoo.comGalmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCJuly 3, 2023 | bizjournals.comMadrigal begins process seeking OK for multibillion-dollar — yet elusive — NASH drugJune 3, 2023 | benzinga.comGalmed Pharmaceuticals Stock (NASDAQ:GLMD), Insider Trading ActivityJune 1, 2023 | finanznachrichten.deGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsJune 1, 2023 | msn.comRecap: Galmed Pharmaceuticals Q1 EarningsJune 1, 2023 | finance.yahoo.comGalmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsMay 17, 2023 | thestreet.comWhy Galmed Pharmaceuticals (GLMD) Stock Is Surging TodayMay 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and Haemonetics (HAE)May 9, 2023 | finance.yahoo.comGalmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)See More Headlines Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/04/2024Today6/15/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLMD CUSIPN/A CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-48.30% Return on Assets-40.97% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book0.12Miscellaneous Outstanding Shares5,050,000Free Float4,046,000Market Cap$1.68 million OptionableNot Optionable Beta0.80 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Allen Baharaff (Age 59)Co-Founder, President, CEO & Chairman Comp: $972.16kMr. Doron Cohen (Age 57)Chief Financial Officer Comp: $245.98kMr. Guy Nehemya (Age 39)COO & Data Protection Officer Comp: $287.04kMr. Yohai Stenzler CPA (Age 41)Chief Accounting Officer Comp: $290.57kDr. Liat Hayardeny (Age 57)Chief Scientific Officer Comp: $47.93kMs. Yael Hollander (Age 41)Vice President of Legal Affairs & Strategy Comp: $134.21kMs. Shani GanonHuman Resources ManagerDr. Tali Gorfine (Age 54)Medical Consultant Comp: $202.76kMore ExecutivesKey CompetitorsPulmatrixNASDAQ:PULMASLAN PharmaceuticalsNASDAQ:ASLNBionomicsNASDAQ:BNOXKinetaNASDAQ:KASunshine BiopharmaNASDAQ:SBFMView All CompetitorsInstitutional OwnershipCVI Holdings LLCSold 194,573 shares on 5/7/2024Ownership: 1.479%View All Institutional Transactions GLMD Stock Analysis - Frequently Asked Questions Should I buy or sell Galmed Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLMD shares. View GLMD analyst ratings or view top-rated stocks. How have GLMD shares performed in 2024? Galmed Pharmaceuticals' stock was trading at $0.4550 on January 1st, 2024. Since then, GLMD shares have decreased by 26.9% and is now trading at $0.3327. View the best growth stocks for 2024 here. Are investors shorting Galmed Pharmaceuticals? Galmed Pharmaceuticals saw a decline in short interest in May. As of May 31st, there was short interest totaling 23,800 shares, a decline of 67.3% from the May 15th total of 72,800 shares. Based on an average daily volume of 178,400 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.4% of the shares of the company are short sold. View Galmed Pharmaceuticals' Short Interest. When is Galmed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our GLMD earnings forecast. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its quarterly earnings data on Thursday, April, 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter. When did Galmed Pharmaceuticals' stock split? Shares of Galmed Pharmaceuticals reverse split on the morning of Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP). Who are Galmed Pharmaceuticals' major shareholders? Galmed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include CVI Holdings LLC (1.48%). How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLMD) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.